Fox Run Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Fox Run Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,441	Closed	-$533K	–	925
2018 Q2	$533K	Buy	+6,441	New	+$497K	0.17%	218
2017 Q3	–	Sell	-9,400	Closed	-$562K	–	962
2017 Q2	$562K	Sell	9,400 -8,300	-47%	-$464K	0.19%	184
2017 Q1	$944K	Buy	+17,700	New	+$1.05M	0.39%	26

Other funds holding ONCE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fox Run Management's ONCE Position: Q3 2018 in Review

Fox Run Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2018, closing a stake of 6,441 shares — an estimated $533K sold.

Fox Run Management first reported a position in ONCE in Q1 2017 and held it in 3 quarters. The position peaked at $944K in Q1 2017. 176 funds tracked by Wall St. Rank hold ONCE as of Q3 2018.

Fox Run Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Fox Run Management sold 6,441 Spark Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $533K.
Fox Run Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
Fox Run Management's Spark Therapeutics, Inc. Common Stock position peaked at $944K in Q1 2017.
176 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Fox Run Management's 13F filing for Q3 2018, filed 5 Oct 2018.